| Trial ID: | L3946 |
| Source ID: | NCT00618995
|
| Associated Drug: |
Comparator: Er Niacin (+) Laropiprant
|
| Title: |
A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00618995/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Comparator: ER niacin (+) laropiprant|DRUG: Comparator: ER niacin|DRUG: Comparator: laropiprant|DRUG: Comparator: placebo
|
| Outcome Measures: |
Primary: Urinary 11-Dehydrothromboxane B2 (11-dTxB2), The creatinine-normalized urine levels of 11-dTxB2 on Day 7 following a 7 day course of daily dosing in the overall 24 hour collection interval, On Day 7 across the 24-hour urinary collection period. | Secondary: Prostaglandin I Metabolite (PGI-M), PGI-M in the Overall 24 Hour Collection Interval Following Administration on Day 7, On Day 7 across the 24-hour urinary collection period.
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
26
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-08
|
| Completion Date: |
2007-12
|
| Results First Posted: |
2009-02-05
|
| Last Update Posted: |
2015-09-07
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00618995
|
